1. Search Result
Search Result
Results for "

X receptor-alpha

" in MedChemExpress (MCE) Product Catalog:

62

Inhibitors & Agonists

2

Fluorescent Dye

2

Peptides

12

Natural
Products

2

Recombinant Proteins

4

Isotope-Labeled Compounds

4

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-175785

    Estrogen Receptor/ERR Aryl Hydrocarbon Receptor Apoptosis MDM-2/p53 Cancer
    X15695 is selective and orally active estrogen receptor (ERα) degrader. X15695 is an aryl hydrocarbon receptor (AHR) ligand. X15695 enables AHR to form a complex with the ERα, promoting its proteasomal degradation. X15695 inhibits the breast cancer cells proliferation, promotes cell cycle block and induces apoptosis. X15695 can be used for the study of breast cancer .
    X15695
  • HY-112461A
    NF449 octasodium
    4 Publications Verification

    P2X Receptor Cardiovascular Disease
    NF449 octasodium is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 octasodium is a Gsα-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs .
    NF449 octasodium
  • HY-N2992

    RAR/RXR Cancer
    16α-Hydroxytrametenolic acid, a natural triterpene, is a potential retinoid X receptor (RXR) selective agonist .
    16α-Hydroxytrametenolic acid
  • HY-133890A
    Tauro-α-muricholic acid sodium
    2 Publications Verification

    T-α-MCA sodium

    Endogenous Metabolite FXR Others
    Tauro-α-muricholic acid (T-α-MCA) sodium is a FXR (Farnesoid X receptor) antagonist (IC50=28μM). Tauro-α-muricholic acid sodium is also a endogenous metabolite that can be found in cecal .
    Tauro-α-muricholic acid sodium
  • HY-101442
    SR9238
    1 Publications Verification

    LXR Metabolic Disease
    SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC50s of 214 nM and 43 nM for LXRα and LXRβ, respectively.
    SR9238
  • HY-143259

    LXR Cancer
    BE1218 is a liver X receptor (LXR) inverse agonist with IC50 values of 9 nM and 7 nM against LXRα and LXRβ, respectively .
    BE1218
  • HY-N2509

    Iristectrigenin B

    LXR Cardiovascular Disease
    Iristectorigenin B (Iristectrigenin B) is a liver X receptor (LXR) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β .
    Iristectorigenin B
  • HY-108652
    α,β-Methylene-ATP trisodium
    1 Publications Verification

    P2X Receptor Inflammation/Immunology
    α,β-Methylene-ATP trisodium is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP trisodium can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP trisodium also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP trisodium can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .
    α,β-Methylene-ATP trisodium
  • HY-112461

    P2X Receptor Cardiovascular Disease
    NF449 is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 is a Gsα-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs .
    NF449
  • HY-106518

    MEN-935 free base

    Adrenergic Receptor Metabolic Disease
    Adimolol (free base) (MEN 935 (free base)) is an antagonist of β- and α-adrenolytic receptor. Adimolol (free base) shows Kis of 5.2 x 10 -7, 1.3 x 10 -5 mol/L at α1 and α2 drenoceptors, respectively. Adimolol (free base) can be used for antihypertensive study .
    Adimolol free base
  • HY-134440A

    P2X Receptor Inflammation/Immunology
    α,β-Methylene-ATP is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .
    α,β-Methylene-ATP
  • HY-134440

    P2X Receptor Inflammation/Immunology
    α,β-Methylene-ATP dilithium is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP dilithium can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP dilithium also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP dilithium can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .
    α,β-Methylene-ATP dilithium
  • HY-134969

    LXR Metabolic Disease
    TFCA is a liver X receptor α (LXRα) antagonist. TFCA inhibits ligand-activated LXRα coactivation and transcriptional expression of the downstream target genes involved in fatty acid synthesis. TFCA attenuates ligand-induced lipogenesis and fatty liver by selectively inhibiting LXRα in the liver .
    TFCA
  • HY-10627A
    GW3965 hydrochloride
    20+ Cited Publications

    LXR Cardiovascular Disease Cancer
    GW3965 hydrochloride is a potent and selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively .
    GW3965 hydrochloride
  • HY-10627
    GW3965
    20+ Cited Publications

    LXR Cardiovascular Disease
    GW3965 is a potent, selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively .
    GW3965
  • HY-108525

    RAR/RXR Cancer
    Fluorobexarotene (compound 20) is a potent retinoid-X-receptor (RXR) agonist, with a Ki value of 12 nM and an EC50 value of 43 nM for RXRα receptor. Fluorobexarotene possesses an apparent RXR binding affinity that is 75% greater than Bexarotene .
    Fluorobexarotene
  • HY-W654353

    T-α-MCA-d4-1 sodium

    Isotope-Labeled Compounds FXR Endogenous Metabolite Others
    Tauro-α-muricholic acid-d4-1 (sodium) is deuterium labeled Tauro-α-muricholic acid (sodium). Tauro-α-muricholic acid (T-α-MCA) sodium is a FXR (Farnesoid X receptor) antagonist (IC50=28μM). Tauro-α-muricholic acid sodium is also a endogenous metabolite that can be found in cecal .
    Tauro-α-muricholic acid-d4-1 sodium
  • HY-133890

    T-α-MCA

    Endogenous Metabolite FXR Cardiovascular Disease Others Metabolic Disease
    Tauro-alpha-muricholic acid (T-alpha-MCA) is a bile acid that belongs to a class of compounds that are synthesized in the liver and play an important role in the digestive process. Tauro-α-muricholic acid activates Farni X receptors (FXR) which are involved in the regulation of bile acid synthesis, metabolism and transport. Tauro-alpha-muricholic acid can be used in the study of metabolic syndrome and cardiovascular disease .
    Tauro-α-muricholic acid
  • HY-W036120

    2,2′,4,4′-Tetrahydroxybenzophenone

    Pregnane X Receptor (PXR) Estrogen Receptor/ERR Others
    Benzophenone-2 (2,2',4,4'-Tetrahydroxybenzophenone) is an endocrine disruptor targeting pregnane X receptor (PXR) and estrogen receptor α (ERα). Benzophenone-2 regulates cytochrome P450 3A (CYP3A) expression by activating PXR. Benzophenone-2 is promising for research of UV filters .
    Benzophenone-2
  • HY-107500
    UVI 3003
    5+ Cited Publications

    RAR/RXR Autophagy Others
    UVI 3003 is a highly selective antagonist of retinoid X receptor (RXR), and inhibits xenopus and human RXRα in Cos7 cells, with IC50s of 0.22 and 0.24 μM, respectively.
    UVI 3003
  • HY-104070

    RAR/RXR Autophagy Cancer
    LG-100064 is a retinoid-X-receptor (RXR) agonist, with EC50s of 330 nM, 200 nM, and 260 nM for RXRα, RXRβ and RXRγ; LG-100064 can be used in the research of cancer.
    LG-100064
  • HY-N15305

    FXR Inflammation/Immunology
    Ferolin is the agonist for farnesoid X receptor (FXR) with an EC50 of 0.56 µM. Ferolin inhibits the expression of inflammatory genes (such as iNOS, IL-1β and TNFα) upon the FXR activation .
    Ferolin
  • HY-144549

    LXR Cardiovascular Disease
    LXR (Liver X receptor) agonist 1 is potent LXR agonist with AC50s of 1.5 nM and 12 nM for LXR-α and LXR-β, respectively. LXR agonist 1 has the potential for the research of atherosclerosis .
    LXR agonist 1
  • HY-174730

    mRNA Inflammation/Immunology
    Human CXCL12 mRNA encodes the human C-X-C motif chemokine ligand 12 (CXCL12) protein, a stromal cell-derived alpha chemokine member of the intercrine family. CXCL12 functions as the ligand for the G-protein coupled receptor, chemokine (C-X-C motif) receptor 4, and plays a role in many diverse cellular functions, including embryogenesis, immune surveillance, inflammation response, tissue homeostasis, and tumor growth and metastasis.
    Human CXCL12 mRNA
  • HY-114994

    TSH Receptor Endocrinology
    MS437 is a potent TSH receptor (TSHR) stimulator with an EC50 value of 13x10 -8 M. MS437 shows potent activation of Gsα, Gαq and Gα12 and up-regulation of thyroglobulin (Tg), sodium iodine symporter (NIS) and TSHR gene expressions .
    MS437
  • HY-116506

    RAR/RXR Reactive Oxygen Species (ROS) Apoptosis Autophagy Cancer
    Bigelovin, a sesquiterpene lactone isolated from Inula hupehensis, is a selective retinoid X receptor α agonist. Bigelovin suppresses tumor growth through inducing apoptosis and autophagy via the inhibition of mTOR pathway regulated by ROS generation .
    Bigelovin
  • HY-101442R

    Reference Standards LXR Metabolic Disease
    SR9238 (Standard) is the analytical standard of SR9238. This product is intended for research and analytical applications. SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC50s of 214 nM and 43 nM for LXRα and LXRβ, respectively.
    SR9238 (Standard)
  • HY-77278

    VD/VDR Aryl Hydrocarbon Receptor LXR PPAR Others
    25-Hydroxytachysterol3 is the metabolite of Vitamin D3 (HY-15398). 25-Hydroxytachysterol3 inhibits the proliferation of epidermal keratinocytes and dermal fibroblasts, stimulates the expression of differentiation- and antioxidant-related genes in keratinocytes. 25-Hydroxytachysterol3 activates vitamin D receptor (VDR) and aryl hydrocarbon receptor (AhR), liver X receptor α/β (LXR α/β) and peroxisome proliferator-activated receptor γ (PPARγ), stimulates the expression of CYP24A1 .
    25-Hydroxytachysterol3
  • HY-10627AR

    Reference Standards LXR Cardiovascular Disease Cancer
    GW3965 (hydrochloride) (Standard) is the analytical standard of GW3965 (hydrochloride). This product is intended for research and analytical applications. GW3965 hydrochloride is a potent and selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively .
    GW3965 hydrochloride (Standard)
  • HY-B1734

    16-DPA

    FXR 5 alpha Reductase Cytochrome P450 Drug Intermediate Cardiovascular Disease Cancer
    16-Dehydropregnenolone acetate (16-DPA), a sterols compound, is an orally active 17α-hydroxylase and 5α-reductase inhibitor. 16-Dehydropregnenolone is also a potent bile acid receptor (BAR)/farnesoid X receptor (FXR) antagonist. 16-Dehydropregnenolone hypolipidemic and anticancer effects. 16-Dehydropregnenolone acetate (16-DPA) is the drug intermediate that can be used for synthesis of Dexamethasone (HY-14648) and related other steroidal pharmacophores .
    16-Dehydropregnenolone acetate
  • HY-100469

    LXR Cardiovascular Disease
    LXRβ agonist-2 is a highly potent and β-selective liver X receptor (LXRβ) agonist with EC50 of 7 nM, displays 28.5-fold selectivity over LXRα (EC50=200 nM) and used in the treatment of atherosclerosis .
    LXRβ agonist-2
  • HY-W778340

    Drug Metabolite Glucocorticoid Receptor Inflammation/Immunology Cancer
    16α-Hydroxy-11-keto prednisolone (compound M-X) is a metabolite of Budesonide (HY-13580). Budesonide, an inhaled glucocortical steroid, is an orally active glucocorticoid receptor agonist. Budesonide is a widely used for study of asthma, rhinitis, and inflammatory bowel disease .
    16α-Hydroxy-11-keto prednisolone
  • HY-170570

    LXR Stearoyl-CoA Desaturase (SCD) Fatty Acid Synthase (FASN) Cancer
    PFM046 is the antagonist for liver X receptor (LXR), that inhibits the activation of LXRα and LXRβ with IC50 of 2.04 μM and 1.58 μM. PFM046 inhibits the expression of SCD1 and FASN, upregulates the expression of ABCA1, and exhibits antitumor efficacy in mouse models .
    PFM046
  • HY-133830

    (3β,7α,24S)-Cholest-5-ene-3,7,24-triol

    Endogenous Metabolite Others
    7α,24(S)-Dihydroxycholesterol ((3β,7α,24S)-Cholest-5-ene-3,7,24-triol) serves as a ligand for liver X receptor (LXR), binding specifically to the ligand binding domains of both LXRα and LXRβ. This compound is synthetically produced from E-α,β-enone, utilizing Arsonium ylide and J-tert-butyldimethylsilyloxy-bisnor-5-cholenaldehyde as starting materials, followed by a series of transformations to yield 7α,24(S)-dihydroxycholesterol.
    7α,24(S)-Dihydroxycholesterol
  • HY-14171
    Bexarotene
    15+ Cited Publications

    LGD1069

    RAR/RXR Autophagy Cancer
    Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM) . Bexarotene can be used for the research of cutaneous T-cell lymphoma.
    Bexarotene
  • HY-122058

    HIV Infection
    KRH-3955 is a CXCR4 antagonist with good bioavailability and potent anti-HIV-1 activity. KRH-3955 can effectively inhibit the replication of X4 HIV-1, including clinical isolates from different donors. KRH-3955 also shows activity against recombinant X4 HIV-1 containing reverse transcriptase, protease and tyrosinase resistance mutations. KRH-3955 can inhibit the binding of SDF-1alpha to CXCR4 and calcium ion signaling through this receptor. KRH-3955 inhibits the binding of an antibody against CXCR4 to CXCR4, showing a potent antagonistic effect on CXCR4. KRH-3955 shows an oral bioavailability of 25.6% in rats and can inhibit the replication of X4 HIV-1 in vivo .
    KRH-3955
  • HY-14171S2

    LGD1069-13C6

    Isotope-Labeled Compounds RAR/RXR Autophagy Cancer
    Bexarotene- 13C6 (LGD1069- 13C6) is 13C labeled Bexarotene. Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM) . Bexarotene can be used for the research of cutaneous T-cell lymphoma.
    Bexarotene-13C6
  • HY-14171R

    LGD1069 (Standard)

    Reference Standards RAR/RXR Autophagy Cancer
    Bexarotene (Standard) is the analytical standard of Bexarotene. This product is intended for research and analytical applications. Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM) . Bexarotene can be used for the research of cutaneous T-cell lymphoma.
    Bexarotene (Standard)
  • HY-128135

    PPAR Inflammation/Immunology
    MHY 553 is a PPARα agonist that is effective when taken orally. MHY 553 helps alleviate liver fat accumulation by increasing fatty acid oxidation and reducing inflammation during the aging process. MHY 553 inhibits the accumulation of triglycerides induced by liver X receptor agonists in HepG2 cells. MHY 553 significantly suppresses the expression of inflammatory mRNA in aging rats .
    MHY 553
  • HY-113259

    Endogenous Metabolite Metabolic Disease
    7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .
    7α-Hydroxy-4-cholesten-3-one
  • HY-W777169

    LGD1069-13C4

    Isotope-Labeled Compounds RAR/RXR Autophagy Cancer
    Bexarotene- 13C4 (LGD1069- 13C4) is the 13C-labeled Bexarotene (HY-14171). Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM) . Bexarotene can be used for the research of cutaneous T-cell lymphoma.
    Bexarotene-13C4
  • HY-117006
    E1231
    1 Publications Verification

    1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one

    Sirtuin Cardiovascular Disease
    E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC50=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (KD=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE -/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases .
    E1231
  • HY-15340
    LG100268
    3 Publications Verification

    LG268

    RAR/RXR Autophagy Metabolic Disease
    LG100268 (LG268) is a potent, selective and orally active retinoid X receptor (RXR) agonist with EC50 values of 4 nM, 3 nM, and 4 nM for RXR-α, RXR-β, and RXR-γ, respectively . LG100268 displays >1000-fold selectivity for RXR over RAR, the Ki values are 3.4 nM, 6.2 nM and 9.2 nM for RXR-α, RXR-β, and RXR-γ, respectively . LG100268 activates RXR homodimers to induce transcriptional activation. LG100268 can be used for the study of lung carcinogenesisy .
    LG100268
  • HY-32350
    Ercalcitriol
    3 Publications Verification

    1α,25-Dihydroxy Vitamin D2

    VD/VDR Drug Metabolite Endogenous Metabolite Metabolic Disease
    Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases .
    Ercalcitriol
  • HY-W587772

    MEHHTP

    Drug Metabolite Metabolic Disease
    Mono (2-ethyl-5-hydroxyhexyl) terephthalate (MEHHTP), a hydroxyl metabolite of the phthalate alternative Di-2-ethylhexyl terephthalate (DEHTP), is a liver X receptor α (LXRα) agonist with a binding energy of -7.41 kcal/mol. Mono (2-ethyl-5-hydroxyhexyl) terephthalate upregulates LXRα downstream targets such as SREBP-1c and FASN and increases lipogenic enzyme activity in hepatocytes, and elevating triglyceride (TG) levels. Mono (2-ethyl-5-hydroxyhexyl) terephthalate is promising for research of nonalcoholic fatty liver disease (NAFLD) .
    Mono(2-ethyl-5-hydroxyhexyl) terephthalate
  • HY-W107616

    Endogenous Metabolite Others
    3,7,11,15-Tetramethyl-2-hexadecen-1-ol can be used to synthesize vitamin E and vitamin E's precursor vitamin K1. 3,7,11,15-Tetramethyl-2-hexadecen-1-ol regulates transcription in cells through the transcription factor PPAR-alpha and the retinoid X receptor (RXR)43 .
    3,7,11,15-Tetramethyl-2-hexadecen-1-ol
  • HY-100277
    Mifobate
    1 Publications Verification

    SR-202

    PPAR Metabolic Disease
    Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects .
    Mifobate
  • HY-113259S

    Endogenous Metabolite Metabolic Disease
    7α-Hydroxy-4-cholesten-3-one-d7 is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .
    7α-Hydroxy-4-cholesten-3-one-d7
  • HY-113545

    9(R)-Hydroxyoctadecadienoic acid

    Endogenous Metabolite Metabolic Disease
    9(R)-HODE is a monohydroxy fatty acid and metabolite of linoleic acid. It is formed from linoleic acid by COX and lipoxygenase (LO).9(R)-HODE induces chemotaxis, increases the levels of chemokine (C-C motif) receptor 9 (CCR9) and chemokine (C-X-C motif) receptor 4 (CXCR4), and inhibits IL-6 release in primary human monocytes. It inhibits CD3α- and CD28-induced proliferation of isolated human peripheral blood lymphocytes when used at a concentration of 25 μg/mL.
    9(R)-HODE
  • HY-113259R

    Reference Standards Endogenous Metabolite Metabolic Disease
    7α-Hydroxy-4-cholesten-3-one (Standard) is the analytical standard of 7α-Hydroxy-4-cholesten-3-one. This product is intended for research and analytical applications. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .
    7α-Hydroxy-4-cholesten-3-one (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: